{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-23-000039","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.868806+00:00","generated_at":"2026-06-15T16:56:09.186303+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas Q1 net loss widens to $81.9M; vepdegestrant combo shows 60.7% CBR","bullets":["Net loss of $81.9M for Q1 2023 vs $63.4M in Q1 2022; revenue increased to $32.5M from $26.5M.","Cash, equivalents, and marketable securities of $1.129B, with expected runway into 2026.","R&D expenses rose to $95.3M (up 49% YoY) driven by increased pipeline investment and Pfizer cost sharing.","Vepdegestrant + palbociclib Phase 1b (Part C) showed 60.7% CBR in heavily pretreated ER+/HER2- mBC patients.","Plans to initiate Phase 3 safety lead-in for vepdegestrant + palbociclib in 1L mBC in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-23-000039","json":"https://secwatch.observer/filing/0001655759-23-000039.json","markdown":"https://secwatch.observer/filing/0001655759-23-000039.md","text":"https://secwatch.observer/filing/0001655759-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000039/0001655759-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000039/arvn-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:56:09.186303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69c7ae3425aca00a1872de89c3e4b85215c5bcd0","claim":"ARVINAS, INC. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"announced its financial results for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575923000039/0001655759-23-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}